Login to Your Account



Financings Roundup

Bringing RNA Back, Mirna Gets $34.5M in Series C

By Catherine Shaffer
Staff Writer

Thursday, October 25, 2012
Amidst a venture capital climate that could most charitably be described as "tough" for early stage biotech, Mirna Therapeutics Inc., of Austin, Texas, completed a $34.5 million Series C financing led by Sofinnova Ventures, with New Enterprise Associates, Pfizer Ventures, Osage University Partners, Correlation Ventures and some existing investors.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription